

“Determination of trimetoquinol in human urine after oral administration of trimetoquinol hydrochloride hydrate by liquid-chromatography-mass spectrometry”

Dr. M. Okano (Anti-Doping Laboratory, Tokyo, Japan)

Trimetoquinol (tretoquinol) is a non-selective beta-2 agonist, which has been explicitly listed as an example of prohibited beta-2 agonists under class S3 of the 2019 *Prohibited List*. Trimetoquinol is used therapeutically for the treatment of asthma (sold as Inolin® in several Asian countries) and is also used as an ingredient of over-the-counter (OTC) cold and flu medications.

Studies on trimetoquinol metabolism have shown that it is excreted in urine either as free form (minor) or phase-II conjugates (glucuronide and sulfate). However, there is no information available about the urinary concentrations after oral administration.

In this study, volunteers were administered 6 mg of oral trimetoquinol hydrochloride hydrate (as per manufacturer's recommendations) to determine the excretion kinetics of trimetoquinol. The results indicate that a conservative reporting limit of 20 ng/mL of trimetoquinol (free plus glucuronide conjugate) should avoid the reporting of an *Adverse Analytical Finding* which may have resulted from the inadvertent use of the trimetoquinol-containing OTC medications before the 2019 *Prohibited List* comes into effect on 1 January 2019.